Latest News-EVEREST MEDICINES Mediaroom_Page

Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients

SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Everest Medicines (HKE...

2023-09-28 07:38 2170

Everest Medicines Enters into Collaboration and License Agreement with Kezar Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and other Asian Markets

SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2023-09-21 07:05 2363

Everest Medicines Announces China Center for Drug Evaluation of NMPA Recommends Priority Review for Cefepime-Taniborbactam for the Treatment of Complicated Urinary Tract Infections, including Pyelonephritis

SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical comp...

2023-09-20 08:26 1971

Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon® for the Treatment of Primary IgA Nephropathy

SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Everest Medicines (HKEX...

2023-08-25 08:15 2325

Everest Medicines Announces Interim Results for First Half of 2023

SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2023-08-24 08:15 4230

Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy

SHANGHAI, Aug. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2023-08-21 08:20 2129

Everest Medicines' Partner Calliditas Therapeutics Announces Full Results From NefIgArd Phase 3 Trial published in The Lancet

SHANGHAI, Aug. 18, 2023 /PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Compan...

2023-08-18 08:41 2511

Everest Medicines' Partner Venatorx Receives FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI)

SHANGHAI, Aug. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmac...

2023-08-15 20:19 2901

Everest Medicines to Announce First Half 2023 Financial Results on August 24, 2023

SHANGHAI, Aug. 9, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"...

2023-08-09 08:06 2254

Everest Medicines Announces Completion of Patient Enrollment in Nefecon® China Open Label Extension Study

SHANGHAI, August 1, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2023-08-01 08:47 2105

Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China

Everest transforms into a commercial-stage innovative biopharmaceutical company SHANGHAI, July 27,...

2023-07-27 08:10 2211

Everest Medicines' Partner Calliditas Therapeutics Makes Data Presentations on Nefecon at European Renal Association - European Dialysis and Transplant Association Congress (ERA-EDTA )

SHANGHAI, June 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2023-06-21 08:15 4603

Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer

SHANGHAI, June 16, 2023 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Compan...

2023-06-16 07:45 3004

Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia

SHANGHAI, May 17, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"...

2023-05-17 07:48 4069

Nefecon Included in the Reimbursement Drug List of "Beijing Puhui Health Insurance Program" as a First-in-Disease Therapy for IgA Nephropathy

SHANGHAI, May 12, 2023 /PRNewswire/ -- An imported version of Nefecon (budesonide) delayed release ...

2023-05-12 07:40 4257

Everest Medicines Launches Nefecon in China's Hainan Boao Pilot Zone as a First-in-Disease Therapy for IgA Nephropathy

SHANGHAI, April 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest," or the "Compan...

2023-04-24 07:44 2787

Everest Medicines Announces Strategic Partnership with Shanghai Pharma Subsidiary to Accelerate the Commercialization of XERAVA in Mainland China

SHANGHAI, April 19, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2023-04-19 08:12 2768

Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy

Nefecon NDA is currently under Priority Review in China and expected to receive approval in 2H 2023...

2023-04-06 07:30 2750

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022

SHANGHAI, March 31, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2023-03-31 07:30 4067

Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves

SHANGHAI, March 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical comp...

2023-03-27 08:15 2436